

BC Cancer Benefit Drug List

August 2019

DEFINITIONS

Class I	Reimbursed for active cancer or approved treatment or approved indication only.
Restricted Funding (R)	Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient.

NOTES

1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required.
2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated.
3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified.
4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or cap_bcca@bccancer.bc.ca

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
abiraterone	tablet	Genitourinary	palliative therapy for metastatic, castration-resistant prostate cancer	UGUPABI	R	
acitretin	capsule	Lymphoma	reversal of early dysplastic and neoplastic stem changes	LYNOS	I	
afatinib	tablet	Lung	first-line treatment of epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer with afatinib	LUAVAFAT	I	
aldesleukin	injectable	Pediatric	pediatric patients with high risk neuroblastoma treated on the ANBL0032 study		I	
alectinib	capsule	Lung	treatment of ALK-positive advanced non-small cell lung cancer with alectinib	ULUAVALE	R	
alemtuzumab	injectable	Lymphoma	treatment of fludarabine-refractory B-chronic lymphocytic leukemia and T-prolymphocytic leukemia	LYALEM	I	
aminolevulinic acid (LEVULAN® KERASTICK®)	topical solution	Skin & Melanoma	topical therapy for skin cancer with PDT (Photodynamic Therapy)	SMPDT	I	Only reimbursable when prescribed by physicians in the Skin Tumour Group within the Skin PDT Program of the BC Cancer Agency
amsacrine	injectable	Leukemia		LKNOS	I	
anagrelide	capsule	Leukemia	patients with thrombocytosis related to a myeloproliferative disorder who have had an inadequate response to or are intolerant of hydroxyurea and/or interferon	LKANAG	I	
anastrozole	tablet	Breast	neoadjuvant or adjuvant therapy for breast cancer using anastrozole in postmenopausal women neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in premenopausal women with high-risk early stage breast cancer first or second line hormonal treatment for advanced breast cancer in postmenopausal women therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAJANAS BRAJLHRHAI BRAVANAS BRAVLHRHA UBRAVPALAI	I	
		Gynecology	hormonal treatment for advanced endometrial cancer in postmenopausal women with contraindications to tamoxifen or intolerant of tamoxifen therapy for advanced ovarian cancer using an aromatase inhibitor	GOENDAI GOOVAI	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
arsenic trioxide	injectable	Leukemia	first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide and tretinoin first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)	LKATOATRA LKATOP LKATOR	I	
asparaginase (KIDROLASE®)	injectable	Leukemia		LKNOS, LYNOS	I	
asparaginase-erwinia (ERWINASE®)	injectable	Leukemia	patients allergic to KIDROLASE®	LKNOS, LYNOS	I	
avelumab	injectable	Skin & Melanoma	second-line treatment of recurrent or metastatic merkel cell carcinoma using avelumab	USMMCAVE	R	
axitinib	tablet	Genitourinary	therapy for metastatic renal cell carcinoma using axitinib	UGUAXIT	R	
azacitidine	injectable	Leukemia	therapy of acute myeloid leukemia using azacitidine and sorafenib therapy of myelodysplastic syndrome	ULKAMLAS ULKMDSA	R R	
bacillus calmette guerin (BCG)	injectable	Genitourinary	therapy for high risk superficial transitional cell bladder cancer palliative therapy for BCG-refractory superficial high-grade transitional cell carcinoma bladder with BCG and Interferon	GUBCG GUBCGIFN	I I	The three substrains of BCG available are considered interchangeable by BC Cancer for the treatment of bladder cancer (i.e., Montreal [PACIS] 120 mg = TICE [OncoTICE] 1 to 8 x 108 CFU = Connaught [Immucyst] 81 mg) BUT only the current contract brand is reimbursed at the current
bendamustine	injectable	Lymphoma	treatment of Non-Hodgkin Lymphoma with bendamustine treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab treatment of relapsed chronic lymphocytic leukemia with bendamustine treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with bendamustine and rituximab treatment of previously untreated chronic lymphocytic leukemia (CLL) with bendamustine and rituximab treatment of rituximab-refractory follicular lymphoma with obinutuzumab in combination with bendamustine	LYBEND LYBENDR LYCLLBEND LYCLLBENDR LYCLLFBR ULYOBGBEND	I I I I I R	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
bevacizumab	injectable	Gastrointestinal	palliative therapy of metastatic colorectal cancer using capecitabine and bevacizumab	GIAVCAPB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine	GICIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine	GICOXB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab	GIFFIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab	GIFFOXB	I	
			patients with relapsed malignant gliomas	CNBEV	I	
			primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel	GOCXCATB	I	
			treatment of platinum resistant epithelial ovarian cancer with bevacizumab and gemcitabine	UGOOVBEVG	R	
			treatment of platinum resistant epithelial ovarian cancer with bevacizumab and pegylated liposomal doxorubicin (CAELYX)	UGOOVBEVL	R	
			treatment of platinum resistant epithelial ovarian cancer with bevacizumab and paclitaxel	UGOOVBEVP	R	
			treatment of platinum resistant epithelial ovarian cancer with bevacizumab and vinorelbine	UGOOVBEVV	R	
			primary treatment or invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel	UGOOVCATB*	R	
bexarotene	capsule	Lymphoma	patients with refractory cutaneous T-cell lymphoma	ULYMFEX	R	Approval from Health Canada Special Access Programme is required for each patient.
bicalutamide	tablet	Genitourinary	nonsteroidal treatment of prostate cancer, at 50 mg po daily	GUPNSAA	I	Not reimbursed for vasomotor symptoms (hot flashes) or high dose monotherapy
bleomycin	injectable	Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide, and cisplatin	GOBEP	I	
		Genitourinary	curative therapy for germ cell cancer using with bleomycin, etoposide, cisplatin for germ cell cancers	GUBEP	I	
		Kaposi's Sarcoma	palliative therapy for Kaposi's sarcoma using vinblastine alternating with vincristine	KSVB	I	Not reimbursed for pleurodesis
	Lymphoma		treatment of Hodgkin lymphoma with doxorubicin, bleomycin, vinblastine, and dacarbazine	LYABVD	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNO)	I	
blinatumomab	injectable	Leukemia	treatment of Philadelphia chromosome negative refractory or relapsed pre-B-cell acute lymphoblastic leukemia with blinatumomab	ULKBLIN	R	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
bortezomib	injectable	Myeloma	maintenance therapy for multiple myeloma using bortezomib for patients with the high-risk chromosome abnormality treatment of multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide as induction pre-stem cell transplant treatment of relapsed multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYBORMTN MYBORPRE MYBORREL UMYDARBD MYMPBOR	I I I R I	
bosutinib	tablet	Leukemia	treatment of chronic myeloid leukemia using bosutinib	ULKCMLB	R	
brentuximab vedotin	injectable	Lymphoma	treatment of Hodgkin lymphoma and anaplastic large cell lymphoma with brentuximab vedotin adjuvant therapy post-autologous stem cell transplant (ASCT) for Hodgkin Lymphoma using brentuximab vedotin	ULYBRENTUX ULYAJBV	R R	
bromocriptine	tablet, capsule	Neuro-Oncology	therapy for pituitary adenomas using bromocriptine	CNB	I	
buserelin	injectable, long-acting injectable	Breast	neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in premenopausal women with high-risk early stage breast cancer neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor combination therapy with tamoxifen as palliative therapy for metastatic breast cancer therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist Genitourinary therapy for prostate cancer using LHRH agonist	BRAJLHRHAI BRAJLHRHT BRAVLHRHA BRAVLHRHT UBRAVPALAI GUPLHRH	I I I I R I	Not reimbursed for endometriosis
busulfan	tablet	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. LKNOS)	I	
	injectable	BMT	myeloablative conditioning therapy prior to hematopoietic stem cell transplantation for myeloid malignancies	BMTIVBUCY	I	
		Pediatric	pediatric patients who cannot swallow oral busulfan		I	
cabazitaxel	injectable	Genitourinary	palliative therapy for metastatic castration resistant prostate cancer using cabazitaxel and prednisone	UGUPCABA	R	
cabergoline	tablet	Neuro-Oncology	therapy for pituitary adenomas using cabergoline	CNCAB	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
capecitabine	tablet	Breast	therapy of adjuvant breast cancer using capecitabine metastatic breast cancer as first line treatment if anthracyclines and taxanes contraindicated, or where side effect profile and/or treatment delivery concerns favour initial use of BRAVACAP; second or third line treatment of metastatic breast cancer that has previously responded to an anthracycline and taxane therapy for metastatic breast cancer using capecitabine and lapatinib combination with trastuzumab (HERCEPTIN) as second-line treatment of HER-2 positive metastatic breast cancer after prior treatment with trastuzumab (HERCEPTIN)	BRAJCAP BRAVCAP UBRAVLCAP UBRAVTCAP	I I R R	
		Gastrointestinal	adjuvant therapy of colon cancer using capecitabine adjuvant combination chemotherapy for stage III and IIB colon cancer with oxaliplatin first line palliative therapy of metastatic or unresectable colorectal adenocarcinoma in a patient either not suitable for or refusing GIIRFUFA palliative therapy of metastatic colorectal cancer using capecitabine and bevacizumab palliative therapy of metastatic neuroendocrine cancer using temozolamide and capecitabine palliative combination chemotherapy for metastatic colorectal cancer using irinotecan and capecitabine in patients unsuitable for G1OLFIRI palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine combination with mitomycin and radiation therapy as curative combined modality therapy for carcinoma of the anal canal palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy adjuvant chemotherapy of gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine	GIAJCAP GIAJCAPOX GIAVCAP GIAVCAPB GIAVTZCAP GICAPIRI GICAPOX GICART GICIRB GICOXB GICPART GIGAJCOX	I I I I I I I I I I I I I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
capecitabine (cont'd)	tablet	Gastrointestinal	adjuvant chemotherapy of gastric cancer patients with completely resected gastric cancer using cisplatin and capecitabine and radiation therapy palliative therapy of metastatic or locally advanced anal squamous cell carcinoma using cisplatin and capecitabine palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using cisplatin, capecitabine and trastuzumab (HERCEPTIN) palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine and oxaliplatin palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab (HERCEPTIN) treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine palliative therapy for metastatic or locally advanced gastric or esophagogastric cancer using epirubicin, oxaliplatin and capecitabine adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine and gemcitabine second line treatment of metastatic or unresectable pancreatic adenocarcinoma using capecitabine adjuvant combination chemotherapy for stage III rectal cancer with oxaliplatin adjuvant capecitabine therapy for stage II and III rectal cancer previously treated with preoperative radiotherapy combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine and radiation therapy combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy treatment of recurrent or metastatic nasopharyngeal cancer with capecitabine	GIGAJCPRT GIGAVCC GIGAVCCT GIGAVCOX GIGAVCOXT GIGECC GIGAVEOCAP GIPAJGCAP GIPAVCAP GIRAJCOX GIRCAP GIRCRT GIRINFRT HNNAVCAP	I I I I I I I I I I I I I I I	
		Head and Neck				

BC Cancer Benefit Drug List

August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
carboplatin	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab (HERCEPTIN) palliative therapy for metastatic breast cancer using cisplatin and gemcitabine palliative therapy for metastatic breast cancer using trastuzumab (HERCEPTIN), paclitaxel and carboplatin as first-line treatment for advanced breast cancer	BRAJDCARBT BRAVGEMP BRAVTPCARB	I	
		Neuro-Oncology	carboplatin and etoposide in the treatment of recurrent ependymoma	CNCARV	I	
		Gastrointestinal	first-line palliative chemotherapy for advanced gallbladder cancer and cholangiocarcinoma using gemcitabine and cisplatin neoadjuvant treatment of oesophageal and gastroesophageal carcinomas using carboplatin, paclitaxel and radiation therapy primary adjuvant treatment of adenocarcinoma/adenosquamous cancer of the cervix with carboplatin and paclitaxel preceding or following irradiation with or without cisplatin	GIAVPG GIENACTRT	I	
		Gynecology	treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin and docetaxel primary treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin and paclitaxel primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel treatment of primarily advanced or recurrent endometrial cancer using carboplatin and docetaxel treatment of primary advanced or recurrent endometrial cancer using carboplatin and paclitaxel primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube, and primary peritoneal cancer, using carboplatin and docetaxel carboplatin and gemcitabine for the treatment of recurrent platinum-sensitive ovarian cancer first or second line therapy for invasive epithelial ovarian cancer using single-agent carboplatin primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel	GOCXAJCAT GOCXCAD GOCXCAT GOCXCATB GOENDCAD GOENDCAT GOOVCAD GOOVCA GOOVCARB UGOOVCATB*	I	R
			primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer, with no visible residual tumour (moderate-high risk) using carboplatin and paclitaxel second line treatment using paclitaxel and carboplatin for epithelial ovarian cancer relapsing after primary treatment primary treatment of visible residual (extreme risk) invasive epithelial ovarian cancer in ambulatory care settings using paclitaxel and carboplatin	GOOVCATM GOOVCATR GOOVCATX	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
carboplatin (cont'd)	injectable	Gynecology	primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using carboplatin and weekly paclitaxel first line treatment of epithelial ovarian cancer using doxorubicin pegylated liposomal (CAELYX™) and carboplatin primary treatment of stage III less than or equal to 1 cm visible residual invasive epithelial ovarian cancer or stage 1 grade 3 or stage II grade 3 papillary serous ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal carboplatin second line treatment for epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin (PLD) and carboplatin treatment of small cell or neuroendocrine carcinoma of gynecologic system origin using paclitaxel, cisplatin, etoposide and carboplatin with radiation	GOOVDDCAT GOOVFPLDC GOOVIPPC GOOVPLDC GOSMCCRT	I	
		Genitourinary	palliative therapy for urothelial carcinoma using cisplatin and gemcitabine adjuvant therapy for stage I high risk seminoma using carboplatin therapy of genitourinary small cell tumors with a platin and etoposide therapy of genitourinary small cell tumors with a platin and etoposide with radiation	GUAVPG GUSCARB GUSCPE GUSCPERT	I	
		Head and Neck	treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine	HNAVUP HNAVPC HNAVPD HNAVPE HNLACAFRT HNNAVFUP HNNAVPE HNNAVPG	I	
		Lung	treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and paclitaxel adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non-small cell lung cancer first-line treatment of advanced non-small cell lung cancer with carboplatin and paclitaxel treatment of advanced non-small cell lung cancer with platinum and gemcitabine first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed	HNNAVPC LUAJPC LUAVPC LUAVPG LUAVPP	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
carboplatin (cont'd)	injectable	Lung	treatment of locally advanced non-small cell lung cancer using carboplatin and paclitaxel with radiation therapy	LULACATRT	I	
			treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy	LULAPER	I	
			treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy	LULAPE2RT	I	
			treatment of thymoma with cisplatin and etoposide	LUOTPE	I	
			treatment of thymoma using cisplatin and etoposide with radiation therapy	LUOTPERT	I	
			therapy of extensive stage small cell lung cancer with cisplatin and etoposide	LUSCP	I	
			therapy of limited stage small cell lung cancer using cisplatin and etoposide with radiation	LUSCPERT	I	
			second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUSCPI	I	
			treatment of advanced stage large B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	ULYRICE	R	
			primary treatment of cancer of unknown primary origin using carboplatin and paclitaxel	PUCAT	I	
		Lymphoma	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMMCPE	I	
				Other tumour site code followed by 'NOS' (e.g. HNNOS)	I	
carfilzomib	injectable	Myeloma	therapy of multiple myeloma using carfilzomib and dexamethasone with or without cyclophosphamide	UMYCARDEX	R	
			therapy of multiple myeloma using carfilzomib, lenalidomide with dexamethasone	UMYCARLD	R	
carmustine	injectable	Lymphoma	topical therapy in cutaneous T-cell lymphoma	LYCARTOP	I	
				Other tumour site code followed by 'NOS' (e.g. LKNOS)	I	
ceritinib	capsule	Lung	treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with ceritinib	ULUAVCER	R	
cetuximab	injectable	Gastrointestinal	palliative third line treatment of metastatic colorectal cancer with wild-type KRAS using cetuximab and irinotecan	GIAVCETIR	I	
			combined cetuximab and radiation treatment for locally advanced squamous cell carcinoma of the head and neck	HNLA CETRT	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
chlorambucil	tablet	Lymphoma	low grade lymphoma and chronic lymphocytic leukemia treatment of indolent B-cell lymphoma with chlorambucil and rituximab treatment of chronic lymphocytic leukemia with chlorambucil and rituximab lymphoma palliative chemotherapy treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab in combination with chlorambucil	LYCHLOR LYCHLRR LYCLLCHLR LYPALL ULYOBCHLOR	I I I I R	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LKNOS, LYNOS)	I	
cisplatin	injectable	Breast	palliative therapy for metastatic breast cancer using cisplatin and gemcitabine	BRAVGEMP	I	
		Neuro-Oncology	adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour	CNCCV	I	
		Gastrointestinal	first-line palliative chemotherapy for advanced gallbladder cancer and cholangiocarcinoma using gemcitabine and cisplatin curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy	GIAVPG GICPART	I I	
			hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	I	Note: cisplatin solution and cisplatin powder (SAP) only funded when prescribed by specialists at BC Cancer VC and Royal Jubilee Hospital
			palliative chemotherapy for upper gastrointestinal tract cancer (gastric, esophageal, gall bladder carcinoma and cholangiocarcinoma) and metastatic anal cancer using infusional fluorouracil and cisplatin combined modality curative therapy for carcinoma of the anal canal using cisplatin, infusional fluorouracil and radiation therapy adjuvant chemotherapy of gastric cancer patients with completely resected gastric cancer using cisplatin and capecitabine and radiation therapy	GIFUC GIFUPART GIGAJCPRT	I I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cisplatin (cont'd)	injectable	Gastrointestinal	palliative therapy of metastatic or locally advanced anal squamous cell carcinoma using cisplatin and capecitabine palliative treatment of metastatic or locally advanced gastric, gastoesophageal junction, or esophageal adenocarcinoma using cisplatin, capecitabine and trastuzumab (HERCEPTIN) palliative treatment of metastatic or inoperable, locally advanced gastric or gastoesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab (HERCEPTIN) treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine palliative therapy of neuroendocrine tumours using cisplatin and etoposide hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel	GIGAVCC GIGAVCCT GIGAVCFT GIGECC GIPE GIPMHIPEC	I I I I I I	
		Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide and cisplatin alternative treatment of gynecological malignancies using cisplatin and paclitaxel treatment of high risk squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix with concurrent cisplatin and radiation therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide invasive epithelial ovarian cancer treatment of small cell or neuroendocrine carcinoma of gynecologic system origin using paclitaxel, cisplatin, etoposide and carboplatin with radiation	GOBEP GOCISP GOCXCRT GOEP GOOV CIS GOSMCCRT	I I I I I I	
		Genitourinary	adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine palliative therapy for urothelial carcinoma using cisplatin and gemcitabine curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin treatment of locally advanced bladder cancer with weekly cisplatin and concurrent radiation treatment of metastatic adrenocortical cancer with doxorubicin, etoposide, cisplatin and mitotane therapy for nonseminoma germ cell cancer using etoposide-cisplatin	GUAJPG GUAVPG GUBEP GUBPWRT GUEDPM GUEP	I I I I I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cisplatin (cont'd)	injectable	Genitourinary	combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin neo-adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine therapy of genitourinary small cell tumors with a platin and etoposide therapy of genitourinary small cell tumors with a platin and etoposide with radiation therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUFUPRT GUMVAC GUNAJPG GUSCPE GUSCPERT UGUTIP GUVEIP GUVIP2	I I I I I R I I	
		Head and Neck	treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum palliative chemotherapy for advanced head and neck squamous cell carcinoma with weekly cisplatin treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide treatment of locally advanced (alternate) head and neck cancer using cisplatin during radiation therapy treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil combined chemotherapy (cisplatin) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil palliative chemotherapy for advanced head and neck nasopharyngeal carcinoma with weekly cisplatin treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine	HNAVFUP HNAVP HNAVPC HNAVPD HNAVPE HNLAALTPRT UHNLADCF HNLAPRT HNNAVFUP HNNAVP HNNAVPE HNNAVPG	I I I I I I R I I I I I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cisplatin (cont'd)	injectable	Head and Neck	induction treatment of locally advanced nasopharyngeal cancer with cisplatin and gemcitabine treatment of locally advanced nasopharyngeal cancer with concurrent cisplatin and radiation treatment of advanced head and neck cancer using cisplatin and fluorouracil treatment of advanced salivary gland cancers with cisplatin and vinorelbine treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide adjuvant cisplatin and vinorelbine following resection of non-small cell lung cancer	HNNLAPG HNNLAPRT HNSAVFUP HNSAVNP HNSAVPAC LUAJNP	I I I I I I	
		Lung	first-line treatment of advanced non-small cell lung cancer with cisplatin and docetaxel treatment for advanced non-small cell lung cancer with cisplatin and vinorelbine treatment of advanced non-small cell lung cancer with platinum and gemcitabine first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy treatment of malignant mesothelioma with platinum and gemcitabine treatment of malignant mesothelioma with platinum and pemetrexed treatment of thymoma with platinum, doxorubicin and cyclophosphamide treatment of thymoma with cisplatin and etoposide treatment of thymoma using cisplatin and etoposide with radiation therapy treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide therapy of extensive stage small cell lung cancer with cisplatin and etoposide therapy of limited stage small cell lung cancer using cisplatin and etoposide with radiation second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUAVDC LUAVNP LUAVPG LUAVPP LULAPERT LULAPE2RT LUMMPG LUMMPP LUOTPAC LUOTPE LUOPTERT LUPUPE LUSCPE LUSCPERT LUSCPI	I I I I I I I I I I I I I I I	
		Lymphoma	treatment of lymphoma with gemcitabine, dexamethasone and cisplatin	LYGDP	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cisplatin (cont'd)	injectable	Lymphoma	treatment of lymphoma with gemcitabine, dexamethasone and cisplatin with rituximab Treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone	LYGDPR	I	
		Sarcoma	adjuvant therapy for osteosarcoma using doxorubicin and cisplatin therapy of advanced osteosarcoma using doxorubicin and cisplatin hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal desmoplastic small round cell tumour (DSRCT) using CISplatin	LYVIPDRT SAJAP SAAVAP	I	
		Skin & Melanoma	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SAHIPEC	I	
		Not Otherwise Specified		SMMCPE	I	
				Other tumour site code followed by 'NOS' (e.g. HNNOS)	I	
cladribine	injectable	Lymphoma	hairy cell leukemia	LYCDA	I	
clodronate	capsule	Breast	bony metastases associated with breast cancer or acute bone pain secondary to metastatic breast cancer	BRAVCLOD	I	Not reimbursed for hypercalcemia
cobimetinib	tablet	Skin & Melanoma	treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib and cobimetinib	USMAVVC	R	
cortisone	tablet	Genitourinary	treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane treatment of adrenal cortical cancer using mitotane	GUEDPM GUMITO	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. GUNOS)	I	
crizotinib	tablet	Lung	second-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with crizotinib first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with crizotinib	LUAVCRIZ LUAVCRIZF	I	
cyclophosphamide	tablet, injectable	BMT	myeloablative conditioning therapy prior to autologous and allogeneic hematopoietic stem cell transplantation for myeloid malignancies using IV busulfan and cyclophosphamide	BMTIVBUCY	I	
		Breast	adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel	BRAJAC BRAJACT	I	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACTG	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cyclophosphamide (cont'd)	tablet, injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel adjuvant therapy for high-risk breast cancer using cyclophosphamide (oral), methotrexate and fluorouracil neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel neoadjuvant or adjuvant therapy for breast cancer using docetaxel and cyclophosphamide adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for breast cancer using trastuzumab (HERCEPTIN), docetaxel and cyclophosphamide palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil palliative therapy for metastatic breast cancer using metronomic low-dose oral cyclophosphamide and methotrexate treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN) neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRAJACTT BRAJACTTG BRAJACTW BRAJCMFPO UBRAJDAC BRAJDC BRAJFEC BRAJFECD BRAJFECDT BRAJTDC BRAVAC BRAVCMF BRAVCMPO BRLAACD BRLAACDT BRLATACG BRLATWAC	I I I I R I I I I I I I I I I I I I	
		Gynecology	palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide	GOOVCYCPO	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cyclophosphamide (cont'd)	tablet, injectable	Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I	
		Head and Neck	paliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil	HNSAVFAC	I	
			treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide	HNSAVPAC	I	
		Lung	treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine	LUOTCAV	I	
			treatment of thymoma with platinum, doxorubicin and cyclophosphamide	LUOTPAC	I	
			treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine	LUSCCAV	I	
		Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	I	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	I	
			treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I	
			treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	I	
			treatment of Hodgkin's disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab	LYCVPR	I	
			therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide	LYCYCLO	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
			treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYFCR	I	
			lymphoma palliative chemotherapy	LYPALL	I	
		Myeloma	treatment of multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide as induction pre-stem cell transplant	MYBOPRE	I	
			treatment of relapsed multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide	MYBORREL	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cyclophosphamide (cont'd)	tablet, injectable	Myeloma	therapy of multiple myeloma using carfilzomib and dexamethasone with or without cyclophosphamide	UMYCARDEX	R	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	UMYDARBD	R	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	I	
			single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant	MYHDC	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W	I	
		Sarcoma	SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT3W	I	
			summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma, osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide	SAAVTC	I	
			treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC	I	
			treatment of sarcomas with pelvic primaries or chemotherapy induced hematuria using vincristine, doxorubicin, cyclophosphamide and mesna	SAVACM	I	
			adjuvant therapy for rhabdomyosarcoma using vincristine, dactinomycin and cyclophosphamide	SAVDC	I	
		Pediatric	adjuvant therapy for rhabdomyosarcoma using vincristine, dactinomycin, cyclophosphamide and mesna	SAVDCM	I	
			treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol*		I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
cyclosporine	capsule	Lymphoma	cytopenias associated with lymphoproliferative disorder of large granular lymphocytes	LYCSPA	I	
			treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cyclosporine	HLHETCSPA	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cytarabine	injectable	Leukemia	therapy of acute myeloid leukemia using low dose cytarabine	LKAMLCYT	I	
		Lymphoma	treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			treatment of lymphoma using intrathecal methotrexate and cytarabine	LYIT	I	
			treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
		Miscellaneous Origins	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine	MOIT	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	
dabrafenib	capsule	Skin & Melanoma	treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib	USMAVDAB	R	
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib and trametinib	USMAVDT	R	
dacarbazine	injectable	Lymphoma	treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine	LYABVD	I	
		Sarcoma	adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAJADIC	I	
			treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAVADIC	I	
		Skin & Melanoma	high dose single agent dacarbazine for metastatic soft tissue sarcoma therapy for metastatic malignant melanoma using high dose single agent dacarbazine	SADTIC	I	
		Not Otherwise Specified		SMDTIC	I	
				Other tumour site code followed by 'NOS' (e.g. SMNOS)	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
dactinomycin	injectable	Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I	
			therapy for low risk gestational trophoblastic neoplasia using methotrexate, leucovorin and actinomycin-D	GOTDLR	I	
		Sarcoma	adjuvant therapy for rhabdomyosarcoma using vincristine, dactinomycin and cyclophosphamide	SAVDC	I	
			adjuvant therapy for rhabdomyosarcoma using vincristine, dactinomycin, cyclophosphamide and mesna	SAVDCM	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. SANOS)	I	
daratumumab	injectable	Myeloma	treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	UMYDARBD	R	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone	UMYDARLD	R	
dasatinib	tablet	Leukemia	chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia	ULKCMRD	R	
daunorubicin	injectable	Leukemia	first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin	LKATOP	I	
				Other tumour site code followed by 'NOS' (e.g. KSNOS)	I	
degarelix	injectable	Genitourinary	therapy for prostate cancer using LHRH antagonist	GUPLHRHA	I	
denosumab (XGEVA®)	injectable	Sarcoma	neoadjuvant use in patients with non-metastatic operable giant cell tumour of the bone	USANADENO	R	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
dexamethasone	tablet	Genitourinary	palliative therapy for metastatic castration resistant prostate cancer using abiraterone and prednisone after failure of docetaxel therapy	UGUPABI	R	
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC	I	
		Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	I	
			treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone	LYASPMEDEX	I	
			treatment of lymphoma with gemcitabine, dexamethasone and cisplatin	LYGDP	I	
			treatment of lymphoma with gemcitabine, dexamethasone and cisplatin with rituximab	LYGDPR	I	
			lymphoma palliative chemotherapy	LYPALL	I	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	I	
			treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone.	LYVIPDRT	I	
		Myeloma	treatment of multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide as induction pre-stem cell transplant	MYBORPRE	I	Not reimbursed for: anti-emetic treatment, steroid replacement therapy, pre-taxane use, or appetite stimulation
			treatment of relapsed multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide	MYBORREL	I	
			therapy of multiple myeloma using carfilzomib and dexamethasone with or without cyclophosphamide	UMYCARDEX	R	
			therapy of multiple myeloma using carfilzomib, lenalidomide with dexamethasone	UMYCARLD	R	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	UMYDARBD	R	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone	UMYDARLD	R	
			treatment of previously untreated multiple myeloma and not eligible for stem cell transplant using lenalidomide with low-dose dexamethasone	UMYLDF	R	
			therapy of relapsed multiple myeloma using lenalidomide with dexamethasone	UMYLDREL	R	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	I	
		Miscellaneous Origins	therapy of multiple myeloma using pomalidomide with dexamethasone	UMYPOMDEX	R	
			patients with primary or metastatic disease exhibiting cerebral edema or CNS swelling; management of malignant brain tumours; management of CNS lymphoma	MODEXA	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
dexamethasone (cont'd)	tablet	Not Otherwise Specified		Other tumour site code followed by 'NOS' (for e.g. CNNOS)	I	Not reimbursed for: anti-emetic treatment, steroid replacement therapy, pre-taxane use, or appetite stimulation
	injectable	Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
dexrazoxane	injectable	Pediatric	pediatric patients with neuroblastoma treated on the CCG AEWS1031 protocol pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		I	
docetaxel	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel	UBRAJDAC	R	
			neoadjuvant or adjuvant therapy for breast cancer using docetaxel and cyclophosphamide	BRAJDC	I	
			neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab (HERCEPTIN)	BRAJDCARBT	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel	BRAJFECD	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN)	BRAJFECDT	I	
			neoadjuvant or adjuvant therapy for breast cancer using trastuzumab (HERCEPTIN), docetaxel and cyclophosphamide combination with doxorubicin and cyclophosphamide as treatment of locally advanced breast cancer	BRAJTDC	I	
			treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN)	BRLAACD	I	
			first, second, or third line treatment of metastatic breast cancer patients with ECOG performance status 0, 1, or 2, and greater than 3 month life expectancy	BRAVDOC	I	
			weekly docetaxel regimen for metastatic breast cancer patients with poor tolerance to 3-weekly docetaxel regimen (BRAVDOC) or high doses of dexamethasone used in BRAVDOC	BRAVDOC7	I	
			palliative therapy for metastatic breast cancer using gemcitabine and docetaxel	BRAVGEMD	I	
			palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab (HERCEPTIN) and docetaxel as first-line treatment for advanced breast cancer	BRAVPTRAD	I	
			with trastuzumab (HERCEPTIN) as first-line treatment for advanced breast cancer refractory to anthracycline adjuvant chemotherapy	BRAVTRAD	I	
			palliative treatment of metastatic esophagogastric adenocarcinoma with docetaxel	GIAVDOC	I	
			perioperative treatment of resectable adenocarcinoma of the stomach, gastoesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin	GIGFLODOC	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
docetaxel (cont'd)	injectable	Gynecology	combination with carboplatin as primary treatment of advanced/recurrent non-small cell cancer of the cervix in ambulatory care settings	GOCXCAD	I	
			treatment of primarily advanced or recurrent endometrial cancer using carboplatin and docetaxel	GOENDCAD	I	
			primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube, and primary peritoneal cancer, using carboplatin and docetaxel	GOOVCAD	I	
			treatment of progressive, platinum-refractory epithelial ovarian carcinoma primary peritoneal	GOVDOC	I	
			combination with gemcitabine for advanced or recurrent uterine sarcoma cancer	GOSADG	I	
		Genitourinary	intravesical use for bladder cancer if BCG and mitomycin C not available	GUNOS	I	
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC	I	
			first-line treatment of castration sensitive, metastatic prostate cancer using docetaxel and androgen deprivation therapy with LHRH agonist or LHRH antagonist with or without antiandrogen, or surgical castration	GUPDOCADT	I	
			treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with docetaxel	HNAVDOC	I	
			treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel	HNAVPD	I	
	Lung		treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil	UHNLADCF	R	
			combination with cisplatin as first line treatment of advanced non-small lung cancer	LUAVDC	I	
			second-line treatment of non-small cell lung cancer	LUAVDOC	I	
	Sarcoma		combination with gemcitabine as second or third line therapy for soft tissue sarcomas	SAAVGEMD	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
doxorubicin	injectable	Breast	adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel palliative therapy for metastatic breast cancer using weekly doxorubicin palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN) neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRAJAC BRAJACT BRAJACTG BRAJACTT BRAJACTTG BRAJACTW UBRAJDAC BRAVA7 BRAVAC BRLAACD BRLAACDT BRLATACG BRLATWAC GIA UGIDEBTACE GIEMBOL GIENDO2 GIPMHIEPC	I I I I I I R I I I I I I I I I I I I	
		Gastrointestinal	palliative therapy for hepatoma using doxorubicin transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-eluting bead (DEB) loaded with doxorubicin hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis			Note: only funded when prescribed by specialists at BC Cancer VC & Royal Jubilee Hospital.
			palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIENDO2	I	
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel	GIPMHIEPC	I	
		Genitourinary	palliative therapy for advanced adrenal cortical cancer using doxorubicin treatment of metastatic adrenal cortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUAVD GUEDPM	I I	Not reimbursed for bladder instillations

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
doxorubicin (cont'd)	injectable	Genitourinary	therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin	GUMVAC	I	Not reimbursed for bladder instillations
		Gynecology	for use in patients with advanced endometrial cancer	GOENDD	I	
		Head and Neck	for use in patients with advanced uterine sarcoma	GOSAD	I	
			palliative therapy for advanced thyroid cancers using doxorubicin	HNOTAVD	I	
			palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil	HNSAVFAC	I	
			treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide	HNSAVPAC	I	
		Lung	treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine	LUOTCAV	I	
			treatment of thymoma with platinum, doxorubicin, and cyclophosphamide	LUOTPAC	I	
			treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine	LUSCCAV	I	
		Lymphoma	treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine	LYABVD	I	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	I	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	I	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
			treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
			lymphoma palliative chemotherapy	LYPALL	I	
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna	SAAI	I	
			doxorubicin for adjuvant use for patients with non-metastatic operable large high grade soft tissue sarcoma	SAAJA	I	
			adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAJADIC	I	
			adjuvant therapy for osteosarcoma using doxorubicin and cisplatin SAIAME alternating with SAVAC or SAVACM with filgrastim support at a TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAAJAP	I	
				SAALT2W	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
doxorubicin (cont'd)	tablet, injectable	Sarcoma	SAIME alternating with SAVAC or SAVACM with filgrastim support at a THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma therapy for advanced soft tissue sarcoma using doxorubicin treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine therapy of advanced osteosarcoma using doxorubicin and cisplatin treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide treatment of sarcomas with pelvic primaries or chemotherapy induced hematuria using vincristine, doxorubicin, cyclophosphamide and mesna	SAALT3W SAAVA SAAVADIC SAAVAP SAVAC SAVACM Other tumour site code followed by 'NOS' (e.g. BRNOS)	I I I I I I I	Not reimbursed for bladder instillations
doxorubicin – pegylated liposomal (CAELYX®)	injectable	Gynecology	treatment of platinum resistant epithelial ovarian cancer with bevacizumab and pegylated liposomal doxorubicin (CAELYX) first line treatment of epithelial ovarian cancer using doxorubicin pegylated liposomal (CAELYX™) and carboplatin treatment of epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin (CAELYX) treatment of epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin (CAELYX) and carboplatin	UGOOVBEVL GOOVFPLDC GOOVLDOX GOOVLPLDC KSLDO	R I I I I	
Kaposi's Sarcoma		Kaposi's sarcoma				
drug-eluting bead (DEB) loaded with doxorubicin (DC Bead® or HepaSphere™)	other	Gastrointestinal	transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-eluting bead (DEB) loaded with doxorubicin	UGIDEBTACE	R	
enzalutamide	tablet	Genitourinary	palliative therapy for metastatic castration resistant prostate cancer using enzalutamide	UGUPENZ	R	
epirubicin	injectable	Breast	adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN)	BRAJFEC BRAJFECD BRAJFECDT	I I I	
		Gastrointestinal	palliative therapy for metastatic or locally advanced gastric or esophagogastric cancer using epirubicin, oxaliplatin and capecitabine	GIGAVEOCAP	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
epirubicin (cont'd)	injectable	Gastrointestinal	palliative therapy for metastatic or locally advanced gastric or esophagogastric cancer using epirubicin, oxaliplatin and infusional fluorouracil treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine	GIGAVEOF	I	
		Genitourinary	intravesical use for bladder cancer if BCG and mitomycin C not available	GIGECC	I	
	Not Otherwise Specified			GUNOS	I	
				Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
eribulin	injectable	Breast	palliative therapy for metastatic breast cancer using eribulin	UBRAVERIB	R	
erlotinib	tablet	Lung	second or third line treatment of advanced non-small cell lung cancer maintenance therapy of advanced non-small cell lung cancer after first-line chemotherapy	LUAVERL	I	
etoposide	capsule/ injectable	Neuro-Oncology	carboplatin and etoposide in the treatment of recurrent ependymoma palliative treatment of patients with recurrent malignant gliomas and ependymoma using low dose etoposide therapy for recurrent malignant brain tumours using temozolamide and etoposide	CNCARV	I	
		Gastrointestinal	palliative therapy of neuroendocrine tumours using cisplatin and etoposide	CNETO	I	
		Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide and cisplatin therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using etoposide treatment of small cell or neuroendocrine carcinoma of gynecologic system origin using paclitaxel, cisplatin, etoposide and carboplatin with radiation therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folic acid), dactinomycin, cyclophosphamide and vincristine	CNTMZETO	I	
	Gynecology			GIPE	I	
				GOBEP	I	
				GOEP	I	
				GOOVETO	I	
				GOSMCCRT	I	
				GOTDEMACO	I	
		Genitourinary	curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin treatment of metastatic adrenocortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUBEP	I	
				GUEDPM	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
etoposide (cont'd)	capsule/injectable	Genitourinary	therapy for nonseminoma germ cell cancer using etoposide-cisplatin therapy of genitourinary small cell tumours with a platin and etoposide therapy of genitourinary small cell tumors with a platin and etoposide with radiation nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUEP GUSCPE GUSCPERT GUVIP2	I	
		Head and Neck	treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide	HNAVPE HNNAVPE	I	
		Lung	treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy treatment of thymoma with cisplatin and etoposide treatment of thymoma using cisplatin and etoposide with radiation therapy treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide therapy of extensive stage small cell lung cancer with cisplatin and etoposide therapy of limited stage small cell lung cancer using cisplatin and etoposide with radiation palliative therapy of extensive stage small cell lung cancer with oral etoposide	LULAPER LULAPE2RT LUOTPE LUOTPERT LUPUPE LUSCPE LUSCPERT LUSCPOE	I	
		Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab lymphoma palliative chemotherapy treatment of advanced stage Large B-Cell Non-Hodgkin's Lymphoma with ifosfamide, carboplatin, etoposide and rituximab treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	HLHETCSPA LYEPOCHR LYIVACR LYPALL ULYRICE LYSMILE	I R	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
etoposide (cont'd)	capsule/injectable	Lymphoma	treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone SAIME alternating with SAVAC or SAVACM with filgrastim support at a	LYVIPDRT	I	
		Sarcoma	TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at a	SAALT2W	I	
			THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma 3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas	SAALT3W	I	
		Skin & Melanoma	etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAVIME3	I	
		Not Otherwise Specified	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMCCPE	I	
				Other tumour site code followed by 'NOS' (e.g. HNNOS)	I	
everolimus	tablet	Breast	therapy for advanced breast cancer using everolimus and exemestane	BRAVEVEX	I	
		Gastrointestinal	treatment of advanced neuroendocrine tumours of gastrointestinal origin (non-functional) using everolimus	UGINETEV	R	Note: AFINITOR® DISPERZ™ formulation not funded
		Genitourinary	palliative treatment of advanced pancreatic neuroendocrine tumours	UGIPNEVER	R	
		Lung	therapy for advanced renal cancer using everolimus	GUEVER	I	
			treatment of advanced neuroendocrine tumours of lung origin (non-functional) using everolimus	ULUNETEV	R	
exemestane	tablet	Breast	neoadjuvant or adjuvant therapy for breast cancer using exemestane in postmenopausal women	BRAJEXE	I	
			neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in premenopausal women with high-risk early stage breast cancer	BRAJLHRHAI	I	
			therapy for advanced breast cancer using everolimus and exemestane first or second line hormonal treatment for advanced breast cancer in postmenopausal women	BRAVEVEX	I	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVEXE	I	
		Gynecology	hormonal treatment for advanced endometrial cancer in postmenopausal women	BRAVLHRHA	I	
				GOENDAI	I	
filgrastim (GRASTOFIL®)	injectable		for inpatient administration only - see BC PharmaCare Special Authority Form for indications covered	FILGRASTIM		Note: NEUPOGEN® brand will only be reimbursed for pediatric inpatient administration

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
fludarabine	injectable/ tablet	Lymphoma	treatment of chronic lymphocytic leukemia or prolymphocytic leukemia with fludarabine and rituximab treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab chronic lymphocytic leukemia or low grade lymphoma treatment of relapsed indolent lymphoma with fludarabine and rituximab pediatric patients with AML treated on the CCG-2961 study	LYCLLFLUDR LYFCR LYFLU LYFLUDR	I	
fludrocortisone	tablet	Genitourinary	treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane mineralocorticoid deficiency associated with mitotane use	GUEDPM GUMITO	I	
fluorouracil	injectable	Breast	adjuvant therapy for high-risk breast cancer using cyclophosphamide (oral), methotrexate and fluorouracil adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN) palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil	BRAJCMFO BRAJFEC BRAJFECD BRAJFECDT BRAVCMF	I	
		Gastrointestinal	adjuvant combination chemotherapy for stage III and stage IIB colon cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin) adjuvant therapy of colon cancer using fluorouracil injection and infusion and leucovorin infusion palliative combination chemotherapy for metastatic colorectal cancer using fluorouracil injection and infusion and folinic acid (leucovorin) infusion combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy	GIAJFFOX GIAJFL GIAVFL GIEFFOXRT	I	
			hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIEMBOL GIENDO2	I	Note: only funded when prescribed by specialists at BC Cancer VC & Royal Jubilee Hospital

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
fluorouracil (cont'd)	injectable	Gastrointestinal	palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin) combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy palliative chemotherapy for upper gastrointestinal tract cancer (gastric, esophageal, gall bladder carcinoma and cholangiocarcinoma) and metastatic anal cancer using infusional fluorouracil and cisplatin combined modality curative therapy for carcinoma of the anal canal using cisplatin, infusional fluorouracil and radiation therapy adjuvant chemotherapy of gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin palliative treatment of metastatic or inoperable, locally advanced gastric or gastoesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab (HERCEPTIN) palliative therapy for metastatic or locally advanced gastric or esophagogastric cancer using epirubicin, oxaliplatin and infusional fluorouracil palliative treatment of metastatic or locally advanced gastric, gastoesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil and leucovorin palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastoesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab perioperative treatment of resectable adenocarcinoma of the stomach, gastoesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin palliative combination chemotherapy for metastatic gastric or esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin) hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin	GIFFIRB UGIFFIRPAN GIFFOXB UGIFFOXPAN GIFIRINOX GIFOLFIRI GIFOLFOX GIFUART GIFUC GIFUPART GIGAJFFOX GIGAVCFT GIGAVEOF GIGAVFFOX GIGAVFFOXT GIGFLODOC GIGFOLFIRI GIHIPEC GIPAJFIROX*	I R I R I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
fluorouracil (cont'd)	injectable	Gastrointestinal	adjuvant combination chemotherapy for stage III rectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin) combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation	GIRAJFFOX	I	
		Genitourinary	fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell carcinoma)	GIRINFRT	I	
		Head and Neck	treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck	GUFPURT	I	
			and neck treatment for locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil	HNAVFUFA	I	
			fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)	HNAVUP	I	
			treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil	UHNLACAFRT	I	
			treatment of advanced head and neck cancer using cisplatin and fluorouracil	HNNAVFUFA	I	
				HNNAVFUP	I	
		Not Otherwise Specified		HNSAVFAC	I	
				HNSAVFUP	I	
				Other tumour site code followed by 'NOS' (e.g. HNNOS)	I	
fluorouracil	topical cream	Skin & Melanoma	skin cancer	SMNOS	I	
flutamide	tablet	Genitourinary	nonsteroidal treatment of prostate cancer	GUPNSAA	I	Not reimbursed for vasomotor symptoms (hot flashes)
gefitinib	tablet	Lung	first-line treatment of epidermal growth factor receptor mutation-positive advanced NSCLC	LUAVGEFF	I	
gemcitabine	injectable	Breast	palliative therapy for metastatic breast cancer using gemcitabine palliative therapy for metastatic breast cancer using gemcitabine and docetaxel	BRAVGEM	I	
			as palliative therapy for metastatic breast cancer using cisplatin and gemcitabine	BRAVGEMD	I	
			treatment of metastatic breast cancer using gemcitabine and paclitaxel	BRAVGEMP	I	
		Gastrointestinal	first-line palliative chemotherapy for advanced gallbladder cancer and cholangiocarcinoma using gemcitabine and cisplatin adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine and gemcitabine	BRAVGEMT	I	
				GIAVPG	I	
				GIPAJGCAP	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
gemcitabine (cont'd)	injectable	Gastrointestinal	adjuvant chemotherapy for pancreatic adenocarcinoma using gemcitabine palliative chemotherapy for pancreatic adenocarcinoma, gallbladder cancer, and cholangiocarcinoma using gemcitabine first line treatment of locally advanced and metastatic pancreatic cancer with paclitaxel-nab (ABRAXANE®) and gemcitabine	GIPAJGEM	I	
			treatment of platinum resistant epithelial ovarian cancer with bevacizumab and gemcitabine	GIPGEM	I	
		Gynecology	carboplatin and gemcitabine for the treatment of recurrent platinum-sensitive ovarian cancer palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer using gemcitabine	GIPGEMABR	I	
			combination with docetaxel for advanced or recurrent uterine sarcoma cancer	UGOOVBEG	R	
			adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine	GOOVCA	I	
			combination with cisplatin for advanced transitional cell carcinoma of the bladder	GOOVGEM	I	
		Genitourinary	intravesical therapy for non-muscle invasive bladder cancer using gemcitabine	GOOVGEM	I	
			combination with cisplatin as neoadjuvant therapy for urothelial carcinoma	GUADG	I	
			combination palliative therapy with paclitaxel in patients with relapsed, cisplatin-refractory germ cell cancers not amenable to cure with surgery or chemotherapy (patients relapsed after BMT are potentially eligible)	GUAPG	I	
		Head and Neck	treatment of loco-regionally recurrent and/or metastatic nasopharyngeal cancer with gemcitabine	HNNAVGEM	I	
			treatment of local-regionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine	HNNAVPG	I	
			as induction treatment of locally advanced nasopharyngeal cancer with cisplatin and gemcitabine	HNNLAPG	I	
		Lung	combination with cisplatin or carboplatin as treatment of advanced non-small cell lung cancer	LUAvg	I	
			treatment of malignant mesothelioma with platinum and gemcitabine	LUMMPG	I	
		Lymphoma	treatment of lymphoma with gemcitabine, dexamethasone and cisplatin in combination with dexamethasone, cisplatin and rituximab for lymphoma	LYGDP	I	
			palliative chemotherapy of lymphomas	LYGDPR	I	
		Sarcoma	combination with docetaxel as second or third line therapy for soft tissue sarcomas	SAAVGEMD	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
goserelin	injectable/ long acting injectable	Breast	neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in premenopausal women with high-risk early stage breast cancer	BRAJLHRHAI	I	Not reimbursed for endometriosis
			neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen	BRAJLHRHT	I	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHA	I	
			combination therapy with tamoxifen palliative therapy for metastatic breast cancer	BRAVLHRHT	I	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	UBRAVPALAI	R	
		Genitourinary	therapy for prostate cancer using LHRH agonist	GUPLRH	I	
hydrocortisone	tablet, injectable	Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSA	I	Not reimbursed for supportive care
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	
hydroxyurea	capsule	Leukemia	Myeloid neoplasms, including but not limited to: Acute myeloid leukemia, Myelodysplastic syndromes (e.g. Refractory anemia), Myeloproliferative disease (e.g. Chronic myeloid leukemia, Polycythemia, Essential thrombocythemia)	LKNOS	I	
		Lymphoma	Lymphoid neoplasms, including but not limited to: Lymphoproliferative disease, Myeloma	LYNOS	I	
ibritumomab 90Y (ZEVALIN®)	injectable	Lymphoma	Palliative therapy for lymphoma using radioimmunotherapy: rituximab-priming for ibritumomab ⁹⁰ Y (ZEVALIN®)	ULYRITZ	R	
ibrutinib	capsule	Lymphoma	treatment of previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma using ibrutinib	ULYFIBRU	R	
			treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using ibrutinib	ULYIBRU	R	
			treatment of relapsed/refractory mantle-cell lymphoma using ibrutinib	ULYMIBRU	R	
idarubicin	injectable	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. BRNOS)	I	
idelalisib	tablet	Lymphoma	treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab	ULYIDELAR	R	
ifosfamide	injectable	Genitourinary	therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin	UGUTIP	R	
			consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna	GUVEIP	I	
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUVIP2	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
ifosfamide (cont'd)	injectable	Lymphoma	treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab treatment of advanced stage Large B-Cell Non-Hodgkin's Lymphoma with ifosfamide, carboplatin, etoposide and rituximab treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone	LYIVACR ULYRICE LYSMILE LYVIPDRT	I R I I	
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma therapy for advanced soft tissue sarcoma using ifosfamide 3-day ifosfamide for use in patients with advanced soft tissue sarcoma 3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAAI SAALT2W SAALT3W SAAVI SAAVI3 SAAVIME3 SAIME	I I I I I I	
		Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. LYNOS)		I	
imatinib	capsule/tablet	Leukemia	therapy for chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia	LKCMLI	I	
		Pediatric	pediatric patients with Philadelphia chromosome positive acute lymphoblastic leukemia		I	
		Sarcoma	adjuvant therapy of C-Kit positive high risk gastrointestinal stromal cell tumours advanced c-kit positive and c-kit negative gastrointestinal stromal cell tumours advanced c-kit positive gastrointestinal stromal cell tumors using 800 mg dosing of imatinib	SAAJGI SAAVGI SAAVGIDD	I I I	
		Skin & Melanoma	treatment of advanced c-kit melanoma using imatinib	USMAVI	R	
imiquimod	topical cream	Skin & Melanoma	topical immunotherapy for in-transit melanoma metastases, cutaneous lymphoma, basal cell carcinoma using imiquimod	SMIMI	I	
inotuzumab ozogamicin	injectable	Leukemia	treatment of relapsed or refractory pre-B-cell acute lymphoblastic leukemia with inotuzumab ozogamicin	ULKINOZ	R	
interferon alfa	injectable	Genitourinary	palliative therapy for BCG-refractory superficial high-grade transitional cell carcinoma bladder with BCG and interferon bladder cancer	GUBCGIFN	I	
		Leukemia		LKNOS	I	
		Lymphoma	lymphoma palliative therapy	LYPALL LYNOS	I I	Not reimbursed for hepatitis, Kaposi's Sarcoma

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
interferon alfa	injectable	Myeloma		MYNOS	I	
		Skin & Melanoma	adjuvant therapy of melanoma patients with palpable lymph nodes or fully resected recurrent disease in lymph nodes	SMAJIFN	I	Not reimbursed for hepatitis, Kaposi's Sarcoma
	eyedrops	Ocular	basal cell carcinoma topical therapy for ocular malignancies	SMNOS OCIFN	I	
ipilimumab	injectable	Genitourinary	treatment of metastatic or advanced renal cell carcinoma using ipilimumab and nivolumab	UGUAVIPNI	R	
		Skin & Melanoma	first-line treatment of unresectable or metastatic melanoma using ipilimumab	USMAVFPI	R	
			treatment of advanced and metastatic melanoma after prior systemic therapy	USMAVPI	R	
			treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab	USMAVIPNI	R	
irinotecan	injectable	Gastrointestinal	palliative third line treatment of metastatic colorectal cancer with wild-type KRAS using cetuximab and irinotecan	GIACETIR	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan and capecitabine in patients unsuitable for GOLFIRI	GICAPIR	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine	GICIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab	GIFFIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab	UGIFFIRPAN	R	
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)	GIFOLFIRI	I	
			second line palliative combination chemotherapy for metastatic gastric or esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin)	GIGFOLFIRI	I	
			palliative chemotherapy for metastatic colorectal cancer using irinotecan	GIIR	I	
			palliative therapy for metastatic colorectal cancer in patients who may not tolerate the 3-weekly irinotecan schedule of GIIR	GIIRINALT	I	
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin	GIPAJFIROX*	I	
	Lung		second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUSCPI	I	
	Pediatric		pediatric patients treated on the COG protocol ARST0531 for intermediate-risk rhabdomyosarcoma		I	
			pediatric patients with recurrent pediatric neuroblastoma treated on the COG protocol ANBL0421		I	
			pediatric patients with high risk renal tumors treated on the COG protocol AREN0321		I	
			pediatric patients with high risk rhabdomyosarcoma treated on the COG protocol ARST0431		I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
irinotecan (cont'd)	injectable	Pediatric	pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol pediatric patients with recurrent/refractory medulloblastomas/CNS PNET of childhood treated on the COG ACNS0821 protocol		I	
isotretinoin (ACUTANE)	capsule	Pediatric	pediatric patients with high risk neuroblastoma pediatric patients treated on the COG protocol ACNS0332 for above average risk medulloblastoma/PNE		I	
lanreotide	injectable	Neuro-Oncology	treatment of growth hormone secreting pituitary adenoma using lanreotide	CNLAN	I	
		Gastrointestinal	symptomatic management of functional carcinoid and neuroendocrine tumours of the GI Tract using lanreotide	UGILAN	R	
lapatinib	tablet	Breast	therapy for metastatic breast cancer using capecitabine and lapatinib	UBRAVLCAP	R	
lenalidomide	capsule	Leukemia	therapy of myelodysplastic syndrome using lenalidomide	ULKMDSL	R	
		Myeloma	therapy of multiple myeloma using carfilzomib, lenalidomide with dexamethasone treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone treatment of previously untreated multiple myeloma and not eligible for stem cell transplant using lenalidomide with low-dose dexamethasone therapy of relapsed multiple myeloma using lenalidomide with dexamethasone maintenance therapy of multiple myeloma using lenalidomide	UMYCARLD UMYDARLD UMYLDF UMYLDREL UMYLENMTN	R R R R R	
lenvatinib	capsule	Head and Neck	therapy for locally recurrent or metastatic, RAI-refractory differentiated thyroid cancer using lenvatinib	UHNOTLEN	R	
letrozole	tablet	Breast	neoadjuvant or adjuvant therapy for breast cancer using letrozole in postmenopausal women neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in premenopausal women with high-risk early stage breast cancer first or second line hormonal treatment for advanced breast cancer in postmenopausal women therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist hormonal treatment for advanced endometrial cancer in postmenopausal women with contraindications to tamoxifen or intolerant of tamoxifen hormonal treatment for advanced ovarian cancer in postmenopausal women	BRAJLET BRAJLHRHAI BRAVLET BRAVLHRHA UBRAVPALAI GOENDAI GOOVAI	I I I I R I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
leucovorin calcium	tablet, injectable	Gastrointestinal	adjuvant combination chemotherapy for Stage III and Stage IIB colon cancer using oxaliplatin, fluorouracil and folinic acid (Leucovorin) adjuvant therapy of colon cancer using fluorouracil injection and infusion and leucovorin infusion palliative combination chemotherapy for metastatic colorectal cancer using fluorouracil injection and infusion and folinic acid (leucovorin) infusion combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin) adjuvant chemotherapy of gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin palliative treatment or metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil and leucovorin palliative treatment or metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin palliative combination chemotherapy for metastatic gastric or esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin) adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin adjuvant combination chemotherapy for stage III rectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIAJFFOX GIAJFL GIAVFL GIEFFOXRT GIFFIRB UGIFFIRPAN GIFFOXB UGIFFOXPAN GIFIRINOX GIFOLFIRI GIFOLFOX GIGAJFFOX GIGAVFFOX GIGAVFFOXT GIGFLODOC GIGFOLFIRI GIPAJFIROX*	I I I I I R I R I I I I I I I I I I I I I	
		Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine therapy for low risk gestational trophoblastic neoplasia using methotrexate, leucovorin and actinomycin-D	GOTDEMACO GOTDLR	I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
leucovorin calcium (cont'd)	tablet, injectable	Head and Neck	fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell carcinoma) fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)	HNAVNUFA HNNAVFUFA	I	
		Lymphoma	treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab treatment of Primary Intracerebral Lymphoma with high dose methotrexate and rituximab treatment of Primary Intracerebral Lymphoma with high dose methotrexate treatment of Leptomeningeal Lymphoma or recurrent Intracerebral Lymphoma with high dose methotrexate treatment of natural killer or T-Cell lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYASPMEDEX LYCHOPRMTX LYCODOXMR LYHDMRP LYHDMTXP LYHDMTXR LYSMILE	I	
		Sarcoma	treatment of osteosarcoma using high dose methotrexate with leucovorin rescue	SAHDMTX	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
leuproreotide	injectable, long acting injectable	Breast	neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in premenopausal women with high-risk early stage breast cancer neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor combination therapy with tamoxifen palliative therapy for metastatic breast cancer therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAJLHRHAI BRAJLHRHT BRAVLHRHA BRAVLHRHT UBRAVPALAI	I I I I R	Leuproreotide acetate IM (LUPRON®) and SC (ELIGARD®) injectables are both reimbursable for prostate cancer indications (GUPLHRH). Not reimbursed for endometriosis.
Genitourinary			therapy for prostate cancer using LHRH agonist	GUPLHRH	I	
lomustine	capsule	Neuro-Oncology	lomustine for treatment of recurrent malignant brain tumors adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine	CNCCNU CNCCV CNMODPCV	I I I	
		Lymphoma	lymphoma palliative chemotherapy	LYPALL	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. CNNOS)	I	
mechlorethamine (chlormethine) (SAP)	topical gel	Lymphoma	topical mechlorethamine in cutaneous T-Cell lymphoma	LYMECHLOR	I	Approval from Health Canada Special Access Programme is required for each patient
medroxyprogesterone	tablet	Gynecology	non-aromatase inhibitor hormonal treatment of endometrial cancer	GOENDH	I	Not reimbursed for appetite stimulation or replacement therapy.
megestrol	tablet	Breast	breast cancer	BRAVMEG	I	
		Gynecology	non-aromatase inhibitor hormonal treatment of endometrial cancer	GOENDH	I	Not reimbursed for appetite stimulation or symptom management
melphalan	tablet, injectable	BMT	conditioning therapy for autologous stem cell transplant using high dose melphalan in the treatment of multiple myeloma	BMTMM0301	I	
		Myeloma	treatment of multiple myeloma using melphalan and prednisone	MYMP	I	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LKNOS)	I	
6-mercaptopurine	tablet	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. LKNOS)	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
mesna	injectable	Genitourinary	consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUVEIP	I	
		Lymphoma	Treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	GUVIP2	I	
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma therapy for advanced soft tissue sarcoma using ifosfamide	LYIVACR	I	
			3-day ifosfamide for use in patients with advanced soft tissue sarcoma 3-day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas etoposide, ifosfamide-mesna (SAIME) for use in sarcomas treatment of sarcomas with pelvic primaries or chemotherapy induced hematuria using vincristine, doxorubicin, cyclophosphamide and mesna adjuvant therapy for rhabdomyosarcoma using vincristine, dactinomycin, cyclophosphamide and mesna mesna dosage modification for hematuria secondary to oxazaphosphorines	SAALT2W	I	Approved for use ONLY as an uro-protector for ifosfamide or high dose cyclophosphamide
		Supportive Care		SAALT3W	I	
				SAAVI	I	
				SAAV13	I	
				SAAVIME3	I	
				SAIME	I	
				SAVACM	I	
	Not Otherwise Specified			SAVDCM	I	
				SCMESNA	I	
				Other tumour site code followed by 'NOS' (e.g. SANOS)	I	
methotrexate	tablet, injectable	Breast	adjuvant therapy for high-risk breast cancer using cyclophosphamide (oral) methotrexate and fluorouracil palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil	BRAJCMFPO	I	Not reimbursed for rheumatoid arthritis, psoriasis.
		Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	BRAVCMF	I	
				GOTDEMACO	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
methotrexate (cont'd)	tablet, injectable	Gynecology	therapy for low risk gestational trophoblastic neoplasia using methotrexate, leucovorin and actinomycin-D	GOTDLR	I	
		Genitourinary	therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin	GUMVAC	I	
		Head and Neck	treatment of head and neck cancer using methotrexate as standard therapy	HNAVM	I	
		Kaposi's Sarcoma	therapy for Kaposi's Sarcoma using vinblastine-vincristine	KSVB	I	
		Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma treatment of burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate treatment of primary intracerebral lymphoma with high dose methotrexate and rituximab treatment of primary intracerebral lymphoma with high dose methotrexate treatment of leptomeningeal lymphoma or recurrent intracerebral lymphoma with high dose methotrexate treatment of lymphoma using intrathecal methotrexate and cytarabine treatment of Burkitt's Lymphoma and Leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab lymphoma palliative chemotherapy treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine treatment of osteosarcoma using high dose methotrexate with leucovorin rescue palliative therapy for aggressive fibromatosis using weekly or alternate week methotrexate and vinblastine intravenously	HLHETCSPA LYASPMEDEX LYCHOPRMTX LYCODOXMR LYEPOCHR LYHDMRP LYHDMTXP LYHDMTXR LYIT LYIVACR LYPALL LYSMILE MOIT SAHDMTX SAMV Other tumour site code followed by 'NOS' (e.g. MYNOS)	I	Not reimbursed for rheumatoid arthritis, psoriasis.
methoxypsonalen	injectable	Lymphoma	treatment of Cutaneous T-cell Lymphoma (Sézary syndrome) with extracorporeal photopheresis	ULYMFECP	R	
methyl aminolevulinate (METVIX®)	topical cream	Skin & Melanoma	topical therapy for skin cancer with PDT (Photodynamic Therapy)	SMPDT	I	Only reimbursable when prescribed by physicians in the Skin Tumour Group within the Skin PDT Program of the BC Cancer Agency
midostaurin	capsule	Leukemia	therapy of FLT3+ acute myeloid leukemia using midostaurin in combination with induction and consolidation chemotherapy	ULKAMLMIDO	R	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
mitomycin	injectable	Gastrointestinal	combined modality therapy for carcinoma of the anal canal using mitomycin, capecitabine and radiation therapy hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy chemotherapy of pseudomyxoma peritonei using intraperitoneal mitomycin and fluorouracil hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation intravesical therapy for non-muscle invasive cell bladder cancer using mitomycin	GICART GIEMBOL GIFUART GIFUIP GIHIPEC GUFUPRT GUBMITO	I	Only funded when prescribed by specialists at BC Cancer VC & Royal Jubilee Hospital
	eye drops	Ocular	eye drops as topical therapy for ocular malignancies	OCMITO	I	
	injectable	Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. GUNOS)	I	
mitotane	tablet	Genitourinary	treatment of advanced adrenal cortical cancer treatment of metastatic adrenocortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUMITO GUEDPM	I	
mitoxantrone	injectable	Genitourinary	palliative therapy for hormone-refractory prostate cancer using mitoxantrone and prednisone	GUPMX	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
nilotinib	tablet	Leukemia	treatment of chronic myeloid leukemia using nilotinib	ULKCMLN	R	
nilutamide	tablet	Genitourinary	prostate carcinoma patients who are intolerant to bicalutamide or flutamide, at 150 mg po daily	GUPNSAA	I	Not reimbursed for vasomotor symptoms (hot flashes)

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
nivolumab	injectable	Genitourinary	treatment of metastatic or advanced renal cell carcinoma using ipilimumab and nivolumab	UGUAVIPNI	R	
			treatment of metastatic or advanced renal cell carcinoma using nivolumab	UGUAVNIV	R	
			treatment of metastatic or advanced renal cell carcinoma using 4-weekly nivolumab	UGUAVNIV4	R	
		Head and Neck	palliative therapy for unresectable, platinum-refractory, recurrent or metastatic squamous cell cancer of the head and neck using nivolumab	UHNAVNIV	R	
			palliative therapy for unresectable, platinum-refractory, recurrent or metastatic squamous cell cancer of the head and neck using 4-weekly nivolumab	UHNAVNIV4	R	
		Lung	treatment of advanced non-small cell lung cancer using nivolumab	ULUAVNIV	R	
			treatment of advanced non-small cell lung cancer using 4-weekly nivolumab	ULUAVNIV4	R	
		Skin & Melanoma	treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab	USMAVIPNI	R	
			treatment of unresectable or metastatic melanoma using nivolumab	USMAVNIV	R	
			treatment of unresectable or metastatic melanoma using 4-weekly nivolumab	USMAVNIV4	R	
obinutuzumab	injectable	Lymphoma	treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab in combination with chlorambucil	ULYOBCHLOR	R	
			treatment of rituximab-refractory follicular lymphoma with obinutuzumab in combination with bendamustine	ULYOBPEND	R	
octreotide	injectable	Neuro-Oncology	treatment of growth hormone secreting pituitary adenoma	CNOCTLAR	I	
		Gastrointestinal	neuroendocrine tumours of the mid-gut or pancreas (including carcinoid tumours and VIPoma) with symptoms due to ectopic hormone secretion	GINOS	I	
	long acting injectable	Neuro-Oncology	treatment of growth hormone secreting pituitary adenoma	CNOCTLAR	I	
		Gastrointestinal	neuroendocrine tumours of the mid-gut or pancreas (including carcinoid tumours and VIPoma) with symptoms due to ectopic hormone secretion	UGIOCTLAR	R	
olaparib	tablet	Gynecology	maintenance treatment of relapsed, BRCA-mutated, platinum sensitive and responsive epithelial ovarian cancer using olaparib	UGOOVOLAPM	R	Note: capsule formulation not funded
osimertinib	tablet	Lung	treatment of EGFR T790M mutation-positive advanced non-small cell lung cancer with osimertinib	ULUAVOSI	R	
oxaliplatin	injectable	Gastrointestinal	adjuvant combination chemotherapy for stage III and IIB colon cancer with capecitabine	GIAJCAPOX	I	
			adjuvant combination chemotherapy for stage III and IIB colon cancer with fluorouracil and folinic acid	GIAJFFOX	I	
			adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin and raltitrexed in patients intolerant to fluorouracil or capecitabine	UGIAJRALOX	R	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine	GICAPOX	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
oxaliplatin (cont'd)	injectable	Gastrointestinal	palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer with fluorouracil and folinic acid adjuvant chemotherapy of gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine adjuvant chemotherapy of gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine and oxaliplatin palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab (HERCEPTIN) palliative therapy for metastatic or locally advanced gastric or esophagogastric cancer using epirubicin, oxaliplatin and capecitabine palliative therapy for metastatic or locally advanced gastric or esophagogastric cancer using epirubicin, oxaliplatin and infusional fluorouracil palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil and leucovorin palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil and leucovorin hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin adjuvant combination chemotherapy for stage III rectal cancer with capecitabine adjuvant combination chemotherapy for stage III rectal cancer with fluorouracil and folinic acid	GICOXB GIEFFOXRT GIFFOXB UGIFFOXPAN GIFIRINOX GIFOLFOX GIGAJCOX GIGAJFFOX GIGAVCOX GIGAVCOXT GIGAVEOCAP GIGAVEOF GIGAVFFOX GIGAVFFOXT GIGFLODOC GIHIPEC GIPAJFIROX* GIRAJCOX GIRAJFFOX	I I I R I I I I I I I I I I I I I I I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
paclitaxel	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab (HERCEPTIN) treatment of metastatic breast cancer using gemcitabine and paclitaxel palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab (HERCEPTIN), and paclitaxel as first-line treatment for advanced breast cancer palliative therapy for metastatic breast cancer using paclitaxel combination with paclitaxel and carboplatin as palliative therapy for metastatic breast cancer as first-line treatment for recurrent breast cancer refractory to anthracycline chemotherapy with paclitaxel as first-line treatment for advanced breast cancer refractory to anthracycline adjuvant chemotherapy palliative therapy for metastatic breast cancer using weekly paclitaxel (given weekly for 3 weeks out of 4 weeks) (replaces BRAVT7) neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel neoadjuvant treatment of esophageal and gastroesophageal carcinomas using carboplatin, paclitaxel and radiation therapy second-line therapy for metastatic or locally advanced gastric or gastroesophageal junction cancer using weekly paclitaxel and ramucirumab hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel alternative treatment of gynecological malignancies using cisplatin and paclitaxel primary adjuvant treatment of adenocarcinoma/adenosquamous cancer of the cervix with carboplatin and paclitaxel preceding or following irradiation with or without cisplatin combination with carboplatin as primary treatment of advanced/recurrent non-small cell cancer of the cervix in ambulatory care settings	BRAJACT BRAJACTG BRAJACTT BRAJACTTG BRAJACTW BRAJTTW BRAVGEMT BRAVPTRAT BRAVTAX BRAVTPCARB BRAVTRAP BRAVTW BRLATACG BRLATWAC GIENACTRT GIGAVRAMT GIPMHIPEC GOCISP GOCXAJCAT GOXCXCAT	I	
		Gastrointestinal				
		Gynecology				

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
paclitaxel (cont'd)	injectable	Gynecology	<p>primarily advanced or recurrent endometrial cancer</p> <p>primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel</p>	GOENDCAT	I	
			<p>primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer, with no visible residual tumour (moderate-high risk)</p>	GOOVCATM	I	
			<p>ovarian cancer relapsing after complete remission of at least 4 months' duration in response to primary treatment with carboplatin and paclitaxel</p>	GOOVCATR	I	
			<p>primary treatment of visible residual (extreme risk) invasive epithelial ovarian cancer</p>	GOOVCATX	I	
			<p>primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel</p>	GOCXCATB	I	
			<p>treatment of platinum resistant epithelial ovarian cancer with bevacizumab and paclitaxel</p>	UGOOVBEVP	R	
			<p>primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using carboplatin and weekly paclitaxel</p>	GOOVDDCAT	I	
			<p>primary treatment of stage III less than or equal to 1 cm visible residual invasive epithelial ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal carboplatin</p>	GOOVIIPC	I	
			<p>progressive, platinum-refractory ovarian carcinoma, primary peritoneal carcinoma or fallopian tube carcinoma</p>	GOVTAX3	I	
			<p>primary management of any gynecologic small cell cancer as part of a combined modality regimen</p>	GOSMCCRT	I	
		Genitourinary	<p>combination palliative therapy with gemcitabine in patients with relapsed, cisplatin-refractory germ cell cancers not amenable to cure with surgery or chemotherapy (patients relapsed after BMT are potentially eligible)</p>	UGUTAXGEM	R	
			<p>therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin</p>	UGUTIP	R	
		Head and Neck	<p>treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin</p>	HNAVPC	I	
			<p>treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and paclitaxel</p>	HNNAVPC	I	
		Lung	<p>adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non-small cell lung cancer</p>	LUAJPC	I	
			<p>combination with carboplatin as first line treatment of advanced non-small cell lung cancer</p>	LUAVPC	I	
			<p>treatment of locally advanced non-small cell lung cancer using carboplatin and paclitaxel with radiation therapy</p>	LULACATRT	I	
		Primary Unknown	<p>primary treatment of cancer of unknown primary origin using carboplatin and paclitaxel</p>	PUCAT	I	
		Pediatric	<p>treatment of recurrent or resistant pediatric malignant germ cell tumors with paclitaxel, ifosfamide and carboplatin (COG protocol AGCT0521)</p>		I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
paclitaxel-nab (ABRAXANE®)	injectable	Breast	palliative therapy for metastatic breast cancer	BRAVABR	I	
		Gastrointestinal	first line treatment of locally advanced and metastatic pancreatic cancer with paclitaxel-nab (ABRAXANE®) and gemcitabine	GIPGEMABR	I	
palbociclib	capsule	Breast	therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	UBRAVPALAI	R	
pamidronate	injectable	Breast	adjuvant treatment of post-menopausal women using pamidronate bony metastases associated with breast cancer for patients who do not tolerate oral clodronate prevention of skeletal related events secondary to breast cancer using pamidronate	UBRAJPAM BRAVCLOD BRAVPAM	R I I	Not reimbursed for hypercalcemia
		Myeloma	multiple myeloma	MYPAM	I	
panitumumab	injectable	Gastrointestinal	palliative third-line treatment of metastatic colorectal cancer using panitumumab with wild type KRAS palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab	GIAVPANI UGIFFIRPAN UGIFFOXPAN	I R R	
pazopanib	tablet	Genitourinary	palliative therapy for renal cell carcinoma using pazopanib	UGUPAZO	R	
pegaspargase (ONCASPAR®)	injectable	Lymphoma	treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYASPMEDEX LYSMILE	I I	
		Pediatric	pediatric patients with leukemia or lymphoma		I	
peginterferon alfa-2a	injectable	Leukemia	therapy of chronic myeloid neoplasms and hypereosinophilic syndrome	LKPEGIFN	I	
pembrolizumab	injectable	Lung	second-line treatment of advanced non-small cell lung cancer using pembrolizumab	ULUAVPMB	R	
		Skin & Melanoma	first-line treatment of advanced non-small cell lung cancer using pembrolizumab	ULUAVPMBF	R	
			treatment of unresectable or metastatic melanoma using pembrolizumab	USMAVPEM	R	
permetrexed	injectable	Lung	second-line treatment of advanced non-small cell lung cancer maintenance therapy of advanced non-small cell lung cancer after first-line chemotherapy	LUAVPEM LUAVPMTN	I I	
			first-line treatment of advanced non-small cell lung cancer with platinum and permetrexed	LUAVPP	I	
			treatment of malignant mesothelioma with platinum and permetrexed	LUMMPP	I	
pertuzumab	injectable	Breast	palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab (HERCEPTIN) and docetaxel as first-line treatment for advanced breast cancer	BRAVPTRAD	I	
			palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab (HERCEPTIN), and paclitaxel as first-line treatment for advanced breast cancer	BRAVPTRAT	I	
plerixafor	injectable		hematopoietic stem cell mobilization	PLERIXAFOR	I	
pomalidomide	capsule	Myeloma	therapy of multiple myeloma using pomalidomide with dexamethasone	UMYPOMDEX	R	
ponatinib	tablet	Leukemia	treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using ponatinib	ULKCMPL	R	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
porfimer (PHOTOFRIN®)	injectable	Gastrointestinal	photodynamic therapy in patients with high-grade dysplasia associated with Barrett's esophagus, and who are not candidates for surgery	UGI0	R	
prednisolone	suspension	Pediatric	pediatric patients		I	
prednisone	tablet	Genitourinary	palliative therapy for metastatic castration resistant prostate cancer using cabazitaxel and predniSONE	UGUPCABA	R	
			palliative therapy for metastatic castration resistant prostate cancer using abiraterone and prednisone after failure of docetaxel therapy	UGUPABI	R	
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC	I	
			palliative therapy for hormone-refractory prostate cancer using mitoxantrone and prednisone	GUPMX	I	
		Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	I	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	I	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
			treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I	
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	I	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab	LYCVPR	I	
			therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide	LYCYCLO	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
			lymphoma palliative chemotherapy	LYPALL	I	
		Myeloma	treatment of multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide as induction pre-stem cell transplant	MYBOPRE	I	
			treatment of relapsed multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide	MYBORREL	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	UMYDARBD	R	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone	UMYDARLD	R	
	tablet	Myeloma	treatment of multiple myeloma using melphalan and prednisone	MYMP	I	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	I	
		Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. LKNOS)		I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
procarbazine	capsule	Neuro-Oncology	modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine	CNMODPCV	I	
			standard procarbazine for second-line treatment of recurrent brain tumor	CNPROC	I	
	Lymphoma		treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			lymphoma palliative chemotherapy	LYPALL	I	
	Not Otherwise Specified			Other tumour site code followed by 'NOS' (e.g. CNNOS)	I	
	tablet	Neuro-Oncology	therapy for pituitary adenomas using quinagolide	CNQUIN	I	
		Genitourinary	therapy for metastatic castration resistant prostate cancer using radium-223	UGUPRAD	R	
raltitrexed	injectable	Gastrointestinal	unresectable or metastatic colorectal adenocarcinoma for patients with previous fluorouracil toxicity	GIRALT	I	
			adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin and raltitrexed in patients intolerant to fluorouracil or capecitabine	UGIAJRALOX	R	
	injectable	Gastrointestinal	second-line therapy for metastatic or locally advanced gastric or gastroesophageal junction cancer using weekly paclitaxel and ramucirumab	GIGAVRAMT	I	
		Sarcoma	third line treatment of advanced gastrointestinal stromal cell tumours (GIST's) using regorafenib	USAAGR	R	
regorafenib	tablet	Gastrointestinal	treatment of advanced hepatocellular carcinoma using regorafenib	UGIREGO	R	
		BMT	pre-emptive rituximab therapy of Epstein-Barr virus related post-transplant lymphoproliferative disease	BMTPDRIT	I	IV formulation only; Rituximab® SC not funded
	IV / 1400 mg SC injectable	Lymphoma	treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab	LYBENDR	I	
			treatment of indolent B-cell lymphoma and chronic lymphocytic leukemia with chlorambucil and rituximab	LYCHLRR	I	
	IV / 1400 mg SC injectable		in combination with CHOP (cyclophosphamide, doxorubicin, prednisone, vincristine), in all stages of newly diagnosed diffuse large B-cell lymphoma and mantle cell lymphoma, advanced stage at diagnosis	LYCHOPR	I	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
	IV / 1600 mg SC injectable		treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with bendamustine and rituximab	LYCLLBENDR	I	
			treatment of chronic lymphocytic leukemia with chlorambucil and rituximab	LYCLLCHLR	I	
	IV / 1600 mg SC injectable		treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I	
			treatment of previously untreated chronic lymphocytic leukemia (CLL) with bendamustine and rituximab	LYCLLFBR	I	
	IV / 1600 mg SC injectable		treatment of chronic lymphocytic leukemia or prolymphocytic leukemia with fludarabine and rituximab	LYCLLFLUDR	I	

BC Cancer Benefit Drug List

August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
rituximab (cont'd)	IV / 1400 mg SC injectable	Lymphoma	treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab combination with CVP for advanced stage indolent lymphoma at diagnosis	LYCODOXMR	I	
	IV / 1400 mg SC injectable		treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYCVPR	I	
	IV / 1400 mg SC injectable	Lymphoma	treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYEPOCHR	I	
	IV / 1400 mg SC injectable	Lymphoma	treatment of relapsed indolent lymphoma with fludarabine and rituximab	LYFLUDR	I	
	IV / 1400 mg SC injectable		in combination with gemcitabine, dexamethasone and cisplatin for lymphoma	LYGDPR	I	
	IV / 1400 mg SC injectable		treatment of primary intracerebral lymphoma with high dose methotrexate and rituximab	LYHDMRP	I	
	IV / 1600 mg SC injectable		treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab	ULYIDELAR	R	
	IV / 1400 mg SC injectable		treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
	IV / 1400 mg SC injectable		treatment of advanced stage large B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	ULYRICE	R	
	IV / 1400 mg SC injectable		follicular lymphoma progressive despite alkylating agents and purine analogues (fludarabine or cladribine), post-transplant lymphoproliferative disease, or newly diagnosed (within 6 months) asymptomatic advanced follicular lymphoma	LYRITUX	I	
	IV injectable		palliative therapy for lymphoma using radioimmunotherapy: rituximab-priming for ibritumomab ⁹⁰ Y (ZEVALIN®)	ULYRITZ	R	IV formulation only; Rituximab® SC not funded
	IV / 1400 mg SC injectable		maintenance treatment of indolent lymphoma	LYRMTN	I	
	IV injectable	Pediatric	pediatric patients treated on the COG protocols ANHL0221 for CD20 positive post-transplant lymphoproliferative disease following solid organ transplantation and ANHL01P1 for newly diagnosed advanced B-cell leukemia/lymphoma		I	IV formulation only; Rituximab® SC not funded
romidepsin	injectable	Lymphoma	treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) with romidepsin	ULYROMI	R	
ruxolitinib	tablet	Leukemia	treatment of symptomatic myelofibrosis with ruxolitinib	ULKMFTRUX	R	
			treatment of polycythemia vera with ruxolitinib	ULKPCVRUX	R	
sargramostim	injectable	Pediatric	pediatric patients with neuroblastoma treated on the COG ANBL0032 protocol		I	
			pediatric patients with relapsed neuroblastoma treated on the COG ANBL1021 protocol		I	
siltuximab	injectable	Lymphoma	treatment of Multicentric Castleman's Disease (MCD) negative for Human Immunodeficiency Virus (HIV) and Human Herpes Virus-8 (HHV-8) Using siltuximab	ULYSILTUX	R	
sorafenib	tablet	Gastrointestinal Genitourinary	sorafenib therapy for advanced hepatocellular carcinoma palliative therapy for renal cell carcinoma in patients after cytokine failure	UGISORAF	R	
		Leukemia	therapy of acute myeloid leukemia using azacitidine and sorafenib	UGUSORAF	R	
				ULKAMLAS	R	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
streptozocin	injectable	Gastrointestinal Not Otherwise Specified	palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIENDO2 Other tumour site code followed by 'NOS' (e.g. GINOS)	I I	Approval from Health Canada Special Access Programme is required for each patient
sunitinib	capsule	Gastrointestinal Genitourinary Sarcoma	as palliative treatment of advance pancreatic neuroendocrine tumours palliative therapy for renal cell carcinoma in patients who are not suitable candidates for interferon second line treatment of advanced c-kit positive gastrointestinal stromal cell tumours (GIST's) after imatinib	UGIPNSUNI UGUSUNI SAAVGS	R R I	
tamoxifen	tablet	Breast Gynecology Head and Neck Sarcoma	neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen neoadjuvant or adjuvant therapy for breast cancer using tamoxifen palliative therapy for breast cancer using a LHRH agonist and tamoxifen palliative therapy for breast cancer endometrial cancer non-aromatase inhibitor hormonal treatment of endometrial cancer therapy for advanced ovarian cancer using tamoxifen treatment of recurrent/metastatic salivary gland cancers recurrent desmoid tumors/aggressive fibromatosis	BRAJLHRHT BRAJTAM BRAVLHRHT BRAVTAM GOENDH GOOVTAM HNSAVTAM SATAM	I I I I I I I I	
temozolomide	capsule	Neuro-Oncology	concomitant (dual modality) and 12 cycles of adjuvant temozolomide for newly diagnosed astrocytomas and oligodendrogiomas with radiation concomitant and adjuvant temozolomide for newly diagnosed malignant gliomas with radiation treatment of elderly newly diagnosed glioma patient with concurrent and adjuvant temozolomide and radiation therapy therapy for newly diagnosed malignant brain tumours with MGMT methylation in elderly patients using temozolomide therapy for malignant brain tumours therapy for malignant brain tumours using metronomic dosing of temozolomide	CNAJ12TZRT CNAJTZRT CNELTZRT CNTEM60 CNTEMOZ CNTEMOZMD	I I I I I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
temozolamide (cont'd)	capsule	Neuro-Oncology	therapy for recurrent malignant brain tumours using temozolamide and etoposide	CNTMZETO	I	
		Gastrointestinal	palliative therapy of metastatic neuroendocrine cancer using temozolamide and capecitabine	GIAVTZCAP	I	
		Pediatric	pediatric patients with brain tumours		I	
			pediatric patients treated on the COG protocol ANBL0421 for recurrent neuroblastoma		I	
			pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		I	
		Sarcoma	therapy for advanced solitary fibrous tumours and hemangiopericytoma using temozolamide and bevacizumab	USATEMBEV	R	
		Skin & Melanoma	palliative therapy for malignant melanoma with brain metastases	SMAVTMZ	I	
temsirolimus	injectable	Genitourinary	therapy for advanced renal cancer using temsirolimus	GUTEM	I	
		Pediatric	treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol*		I	
teniposide	injectable	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. GUNOS)	I	
testosterone enanthate	injectable	Breast	palliative therapy for metastatic breast cancer	BRAVTEST	I	Not reimbursed for symptom management or appetite stimulation
thioguanine	tablet	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. LYNSOS)	I	
thiotepa	injectable	Miscellaneous Origins	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine	MOIT	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. GUNOS)	I	
thyrotropin alfa	injectable	Head and Neck	radioiodine imaging in patients with thyroid cancer and treatment	HNOTTSH	I	
topotecan	injectable	Gynecology	treatment of relapsed/progressive epithelial ovarian, fallopian tube or primary peritoneal cancer using topotecan	GOOVTOP	I	
		Lung	second line treatment of recurrent small cell lung cancer	LUSCTOP	I	
		Pediatric	pediatric sarcoma		I	
			intermediate-risk (COG ANBL0532) and high risk (COG ANBL0531) pediatric neuroblastoma		I	
		Sarcoma	summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma, osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide	SAAVTC	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
trametinib	tablet	Skin & Melanoma	treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib and trametinib treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using trametinib	USMAVDT USMAVTRA	R R	
trastuzumab (HERCEPTIN)	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN) neoadjuvant or adjuvant therapy for breast cancer using trastuzumab (HERCEPTIN), docetaxel and cyclophosphamide adjuvant therapy for breast cancer using trastuzumab (HERCEPTIN) following the completion of chemotherapy (sequential) adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab (HERCEPTIN) palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab (HERCEPTIN) and docetaxel as first-line treatment for advanced breast cancer palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab (HERCEPTIN), and paclitaxel as first-line treatment for advanced breast cancer combination with capecitabine as second-line treatment of HER-2 positive metastatic breast cancer after prior treatment with trastuzumab (HERCEPTIN) combination with paclitaxel and carboplatin as palliative therapy for metastatic breast cancer as first-line treatment for recurrent breast cancer refractory to anthracycline chemotherapy single agent therapy for metastatic breast cancer progressing after 1 prior regimens (e.g., taxane) and responding to trastuzumab (HERCEPTIN) in combination with paclitaxel, with paclitaxel and carboplatin, or with vinorelbine with docetaxel as first-line treatment for advanced breast cancer refractory to anthracycline adjuvant chemotherapy with paclitaxel as first-line treatment for advanced breast cancer refractory to anthracycline adjuvant chemotherapy combination with 3-weekly vinorelbine as palliative therapy for metastatic breast cancer	BRAJACTT BRAJACTTG BRAJDCAWT BRAJFECDT BRAJTDC BRAJTR BRAJTTW BRAVPTRAD BRAVPTRAT UBRAVTCAP BRAVTPCARB BRAVTR BRAVTRAD BRAVTRAP BRAVTRVIN	I I I I I I I I I R I I I I I I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
trastuzumab (HERCEPTIN) (cont'd)	Injectable	Breast	treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (HERCEPTIN)	BRLAACDT	I	
		Gastrointestinal	palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using cisplatin, capecitabine and trastuzumab (HERCEPTIN)	GIGAVCCT	I	
			palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab (HERCEPTIN)	GIGAVCFT	I	
			palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab (HERCEPTIN)	GIGAVCOXT	I	
			palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab	GIGAVFFOXT	I	
			continuation of palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using trastuzumab (HERCEPTIN)	GIGAVTR	I	
trastuzumab emtansine (KADCYLA)	injectable	Breast	palliative therapy for metastatic breast cancer using trastuzumab emtansine (KADCYLA)	UBRAVKAD	R	
tretinoin (VESANOID®)	capsule	Leukemia	acute promyelocytic leukemia first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide and tretinoin	LKNOS LKATOATRA	I I	
			first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)	LKATOP LKATOR	I I	
vandetanib	tablet	Head and Neck	treatment for locally advanced or metastatic medullary thyroid cancer using vandetanib	UHNOTVAN	R	
vemurafenib	tablet	Skin & Melanoma	treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib and cobimetinib	USMAVVEM USMAVVC	R R	
vinblastine	injectable	Genitourinary	therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin	GUMVAC	I	
		Kaposi's Sarcoma	consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna	GUVEIP	I	
		Lymphoma	therapy for Kaposi's Sarcoma using vinblastine-vincristine treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine	KSVB	I	
		Sarcoma	lymphoma palliative chemotherapy palliative therapy for aggressive fibromatosis using weekly or alternate week methotrexate and vinblastine intravenously	LYABVD LYPALL SAMV	I I I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vincristine	injectable	Neuro-Oncology	adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	CNCCV CNMODPCV	I	
		Gynecology	therapy for Kaposi's Sarcoma using vinblastine-vincristine	GOTDEMACO	I	
		Kaposi's sarcoma	treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine	KSVB	I	
		Lung	treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine	LUOTCAV	I	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LUSCCAV	I	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOP	I	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
			treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I	
			treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	I	
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab	LYCVPR	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
			lymphoma palliative chemotherapy SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	LYPALL	I	
		Sarcoma	SAIME alternating with SAVAC or SAVACM with filgrastim support at a <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W SAALT3W	I	
			treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vincristine (cont'd)	injectable	Sarcoma	treatment of sarcomas with pelvic primaries or chemotherapy induced hematuria using vincristine, doxorubicin, cyclophosphamide and mesna	SAVACM	I	
			adjuvant therapy for rhabdomyosarcoma using vincristine, dactinomycin and cyclophosphamide	SAVDC	I	
			adjuvant therapy for rhabdomyosarcoma using vincristine, dactinomycin, cyclophosphamide and mesna	SAVDCM	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	
vinorelbine	injectable	Breast	palliative therapy for metastatic breast cancer combination with 3-weekly trastuzumab (HERCEPTIN) as palliative therapy for metastatic breast cancer	BRAVNAV	I	
		Gynecology	treatment of platinum resistant epithelial ovarian cancer with bevacizumab and vinorelbine	UGOOVBEVV	R	
			palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer	GOOVVIN	I	
		Head and Neck	combination with cisplatin as treatment of advanced salivary gland cancers with cisplatin and vinorelbine	HNSAVNP	I	
			adjuvant cisplatin and vinorelbine following resection of stage I, II and IIIA non-small cell lung cancer	LUAJNP	I	
			combination with cisplatin as treatment for advanced non-small cell lung cancer	LUAVPN	I	
		Lung	advanced non-small cell lung cancer in elderly patients	LUAVVIN	I	
			malignant mesothelioma	LUMMVIN	I	
			pediatric patients treated on the COG protocol AHOD0521 for refractory/recurrent Hodgkin's disease		I	
		Pediatric	treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol*		I	
vismodegib	capsule	Skin & Melanoma	treatment of metastatic or locally advanced basal cell carcinoma	USMAVVIS	R	
yttrium-90	injectable	Gastrointestinal	transarterial radioembolisation of hepatocellular carcinoma with portal venous invasion or T3 tumours, and metastatic neuroendocrine tumours	UGIYTT	R	
zoledronic acid	injectable	Breast	adjuvant treatment of post-menopausal women using zoledronic acid	BRAJZOL5	I	
			adjuvant treatment breast cancer in post-menopausal women using 3-monthly zoledronic acid	BRAJZOL2	I	
			treatment of acute bone pain secondary to breast cancer metastases using IV zoledronic acid	BRAVZOL	I	
			treatment of multiple myeloma with zoledronic acid	MYZOL	I	

BC Cancer Benefit Drug List
August 2019

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
Protocol Code Definitions						
Bone Marrow Transplantation		BMT				
Breast		BR				
Gastrointestinal		GI				
Genitourinary		GU				
Gynecologic		GO				
Head and Neck		HN				
Kaposi's sarcoma		KS				
Leukemia		LK				
Lung		LU				
Lymphoma		LY				
Miscellaneous Origin		MO				
Myeloma		MY				
Neuro-Oncology		CN				
Ocular		OC				
Primary Unknown		PU				
Sarcoma		SA				
Skin & Melanoma		SM				